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Purpose: The American College of Chest Physicians (ACCP) has
established evidence-based guidelines for the evaluation and treat-
ment of patients with lung cancer. Physicians’ beliefs and practice
patterns may differ significantly from established guidelines. We
conducted a survey to assess and compare physician beliefs against
the evidence-based guidelines.
Methods: A survey was sent by electronic mail (e-mail) in March
2006 to 2100 randomly selected physicians who were members of
the ACCP practicing in the United States, followed by two reminder
e-mails.
Results: Three hundred forty-seven surveys were completed and
evaluable. The majority (84%) of the respondents reported having
read, consulted, or used the guidelines to set practice policies, and
75% found the guidelines helpful. The respondents’ practice beliefs
were in agreement with the guidelines on the evaluation of operable
patients with enlarged mediastinal lymph nodes, the role of chemo-
therapy in the treatment of stage III disease, and the evaluation of a
solitary pulmonary nodule. Nevertheless, a significant percentage of
respondents’ practice beliefs differed from the guidelines on issues
such as screening for lung cancer, the survival benefit of chemotherapy
in stage IV disease, and postoperative radiation therapy. Only a minor-
ity of respondents believed that chemotherapy improved quality of life
in stage IV disease. The survey results indicate that there has been
acceptance of the adjuvant chemotherapy and increasing integration of
positron emission tomography in the evaluation of a solitary pulmonary
nodule and in staging the mediastinum.
Conclusions: The majority of physicians found the evidence-based
guidelines beneficial; nevertheless, practice beliefs differ from the
guidelines in select areas.
Key Words: Survey, Evidence-based medicine, Chemotherapy,
Positron emission tomography scan, Quality of life, Combined
modality therapy.
(J Thorac Oncol. 2007;2: 819–826)
Lung cancer remains the leading cause of cancer death forboth men and women in the United States. It is estimated
that in 2007, more people will die from lung cancer than from
colon cancer, breast cancer, and prostate cancer combined.1
Pulmonologists and thoracic surgeons see a high concentra-
tion of lung cancer patients and are frequently the first
physicians to discuss the lung cancer diagnosis with the
patient and the patient’s family. The initial physician’s opin-
ions and attitudes can significantly influence the patient’s
treatment preferences, and these physicians frequently serve
as referents to other specialists, including medical oncologists
and radiation oncologists.
A survey we conducted in 1999 revealed that some
physicians’ beliefs in the evaluation and treatment of non-
small cell lung cancer (NSCLC) were not supported in the
medical literature.2 Since the survey in 1999, the American
College of Chest Physicians (ACCP) has established evi-
dence-based guidelines for the diagnosis and management of
NSCLC.3 The purpose of these evidence-based guidelines
was to provide physicians with a concise, accurate summary
of the medical literature. Nevertheless, treatment beliefs and
practice patterns can vary significantly from evidence-based
guidelines, and this can adversely impact the quality of
patient care. Using a survey similar to the one used in 1999,
we sought to describe the beliefs among pulmonologists and
thoracic surgeons and to assess whether the treatment beliefs
were in agreement with the evidence-based guidelines.
MATERIALS AND METHODS
The eligible group of survey recipients consisted of
ACCP members practicing adult patient care in the United
States. There were 5000 eligible members, and 2100 physi-
cians were selected randomly. The survey (Figure 1) was sent
in March 2006, using the e-mail addresses available to the
ACCP, followed by two reminder e-mails. Select questions
were open ended, asking for written answers. The responses
from specialties other than thoracic surgery were combined
with the pulmonary responses, and these were compared with
the responses of the thoracic surgeons. Respondents who
reported never having heard or read the guidelines were
combined, and respondents who reported reading part of the
guidelines or using them in the management of patient care or
to set practice policies were combined. For the questions
concerning the effectiveness of adjuvant chemotherapy, post-
operative radiotherapy (PORT), and the role of chemotherapy
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in combination with radiotherapy in stage III disease, the
responses indicating a belief in beneficial or detrimental
effects on survival were combined.
Statistical Analysis
General association between beliefs in therapy and
physician characteristics was assessed using Pearson 2 test
or Fisher’s exact test (for contingency tables with small and
zero cell counts). For ordered response variables (e.g., im-
proved, no effect, and worse in survival), the Mantel–Haen-
szel 2 statistic was used to test mean score-location response
shifts. All analyses were two sided. A p value 0.05 was
considered statistically significant. Statistical analyses were
performed with SAS statistical software, version 9.1 (SAS
Institute Inc., Cary, NC).
RESULTS
Response Rates
One hundred nine surveys were returned as undeliver-
able, and seven people declined to participate in the survey.
Of the remaining 1984 survey recipients, there were 400
responses (20%). Thirty respondents stated that they did not
treat adult patients or patients with NSCLC, and 19 respon-
dents began the survey but elected not to complete it. Thus,
347 recipients completed the entire survey.
Respondent Characteristics
General demographic and practice characteristics of
respondents are presented in Table 1. Two respondents were
in the field of general medicine, and 15 respondents were in
specialties other than thoracic surgery. A higher percentage
of the thoracic surgery respondents practice at academic
FIGURE 1. Survey sent to 2100 American College of Chest Physicians regarding their beliefs in the evaluation and treatment
of non-small cell lung cancer.
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centers (58% versus 33%, respectively) compared with the
pulmonary medicine respondents, and a higher percentage of
thoracic surgery respondents reported case loads of more than
25 patients per year (89% and 55%, p 0.0001). Eighty-four
percent of respondents had read at least part of the guidelines,
used them in the management of patients, or used them to set
practice policies, and 75% reported finding the guidelines
helpful to their practice. Twenty-eight percent responded that
the guidelines were definitely helpful to their practice, and
47% responded that the guidelines were helpful sometimes.
Beliefs in Screening and Evaluation of a
Pulmonary Nodule
Participants were asked whether they believed in
screening tests for patients perceived as high risk for devel-
oping lung cancer. We did not provide a specific definition of
high risk, because we wanted to leave this to each respon-
dent’s judgment. Fifty-four percent of respondents expressed
a belief in screening (Table 2). Thoracic surgery had a
statistically significant association with a belief in screening.
When respondents were presented with a clinical history of a
smoker with a spiculated 1.5-cm pulmonary nodule, most
respondents (40%) elected to pursue a positron emission
tomography (PET) scan, and a significant percentage of
respondents elected to pursue a surgical procedure or biopsy
(Table 3). Seven percent of respondents elected to answer this
question with an open-ended response; the most frequent
response was to perform a wedge resection and, if pathology
was positive for malignancy, to perform a lobectomy and
lymph-node dissection, or to perform a mediastinoscopy and
then a lobectomy if the mediastinal lymph nodes were neg-
ative for malignancy.







(n  62) p
Gender
Male 90 90 92 0.81
Female 10 10 8
Principal practice
setting
Solo 12 12 6 0.004
Small group (2–9) 33 34 27




Academic 38 33 58
Other 2 2 3
Annual caseload
Patients
10 11 12 5 0.0001
11–25 28 33 6
25 61 55 89
Completion of
medical training
Before 1985 36 39 26 0.08
1985–1995 42 41 44
After 1995 22 20 31
a Includes physicians who listed their specialty as “other” or general medicine.
TABLE 2. Beliefs in Screening of High-Risk Patients for Lung
Cancer
Belief in Screening
Characteristic Yes (%) p
All respondents 54






TABLE 3. Evaluation of Spiculated 1.5-cm Nodule in a
Smoker
Diagnostic Test Percentage
Positron emission tomography scan 40
Biopsy (transthoracic or bronchoscopy) 19
Lobectomy 16
Thoracoscopic wedge resection 14
Other 7
Mediastinscopy 2
Repeat computed tomography scan 1
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Mediastinal Staging
Two questions specifically asked respondents’ opinions
of the preferred method of staging the mediastinum in a
potentially operable patient: one with enlarged lymph nodes
(defined as 1 cm on computed tomography [CT] scan) and
one with a patient with a normal-sized node (defined as 1
cm on CT scan). Because there are multiple different methods
of histologically or cytologically evaluating mediastinal
lymph nodes, the method was not specified.
For the patient scenario with enlarged lymph nodes, the
majority of the respondents (77%) recommended histological
or cytological evaluation (Table 4). A significant percentage
of respondents (17%) believed that PET scans were the
optimal method of evaluating the enlarged lymph nodes. Five
percent of respondents elected to answer with open-ended
responses; the most frequent answers included a combination
of PET and invasive staging (3%), combined PET/CT (1%),
and endobronchial ultrasound and/or endoscopic ultrasound
(1%). In the patient scenario of an operable patient with
normal-sized lymph nodes on CT scan, the percentages of
respondents who elected to pursue PET scanning and histo-
logical or cytological evaluation were approximately equal at
42% and 38%, respectively (Table 4). Preference of staging
method was significantly associated with specialties (p 
0.001). Thoracic surgeons elect to pursue a PET scan at a
higher rate than histological staging (50% versus 18%),
whereas pulmonary medicine respondents elect PET scanning
and histological staging almost equally (40% versus 42%). A
significant percentage (9%) of respondents selected open-
ended responses for this question. The most frequent re-
sponses were selective use of PET scanning and/or invasive
procedures, depending on tumor stage or size, histology, and
location (4%); a combined PET/CT scan (3%); lymph-node
exploration at the time of surgery (1%); and endobronchial or
endoscopic ultrasound (1%).
Survival Estimates
To assess the respondents’ perceptions of the prognosis
of NSCLC, respondents were asked to estimate the 5-year
overall survival rate for stage I NSCLC. The majority of
respondents (62%) selected 65%, and 26% of respondents
estimated a survival rate of 85% (Table 5). There was a
statistically significant difference in the response depending









Lymph node 1 cm
All respondents 1 77 17 6
Pulmonary medicine 1 74 19 6 0.12
Thoracic surgery 0 89 10 2
Annual case load
2–10 3 74 18 5 0.21
11–25 1 70 20 8
25 0 81 15 4
ACCP guidelines
Never read 0 72 24 4 0.46
Read 1% 78 16 6
Lymph node 1 cm
All respondents 11 38 42 9
Pulmonary medicine 11 42 40 7 0.001
Thoracic surgery 11 18 50 21
Annual case load
2–10 8 40 50 3 0.23
11–25 1 70 20 8
25 0 81 15 4
ACCP guidelines
Never read 18 40 39 2 0.05
Read 10 38 42 11
CT, computed tomography; PET, positron emission test; ACCP, American College
of Chest Physicians.
TABLE 5. Estimated 5-year Survival Rate for Stage I Non-
small Cell Lung Cancer
Estimated 5-Year Survival Rate (%)
25% 45% 65% 85% Other p
All respondents 1 6 62 26
Pulmonary medicine 1 7 61 27 5 0.42
Thoracic surgery 2 2 68 26 3
Medical training
Before 1985 2 9 61 22 5 0.02
1985–1995 0 3 69 24 4
After 1995 0 5 51 38 5











All respondents 85 15 1
Pulmonary medicine 83 17 1 0.06
Thoracic surgery 95 3 2
Annual case load
2–10 78 22 0 0.24
11–25 83 17 0
25 87 12 1
Postoperative radiotherapy
impact on survival
All respondents 35 58 7
Pulmonary medicine 37 59 4 0.007
Thoracic surgery 28 53 18
Annual case load
2–10 46 51 3 0.017
11–25 40 51 4
25 31 60 9
ACCP guidelines
Never read 40 56 4 0.024
Read 30 61 10
ACCP, American College of Chest Physicians.
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on the year of completion of medical training. For respon-
dents graduating after 1995, a higher percentage of respon-
dents selected a 5-year survival rate of 85%.
Treatment Beliefs
To assess beliefs regarding treatment efficacy, therapy
options were offered by disease stage and potential benefit.
The majority of respondents (82%) believed that adjuvant
chemotherapy provided an improvement in 5-year survival
(Table 6). In regard to PORT, the majority (58%) of respon-
dents believed that it had no effect on survival, whereas 35%
believed it offered an improvement in survival (Table 6). A
substantial percentage (30%) of respondents who had read the
guidelines believed that it improved survival. In the treatment
of unresectable stage III NSCLC, the majority (85%) of
respondents believed that the combination of chemotherapy
and radiation therapy was superior to radiation therapy alone
(Table 7). A lower percentage (60%) believed that chemo-
therapy provided a survival benefit in stage IV disease, and a
minority (31%) believed that it improved quality of life
(Table 8). A significantly higher percentage of thoracic sur-
geons reported a belief in the survival benefits of chemother-
apy in stage IV disease than did respondents of other spe-
cialties (74% versus 56%, p  0.01). Among the respondents
who had read the guidelines, 41% believed that chemother-
apy did not improve survival, and 47% believed that it
worsened the patient’s quality of life.
DISCUSSION
The guidelines recommend against screening for lung
cancer with chest x-ray and sputum cytology, and they
recommend that patients undergo screening with a CT scan
only in the context of a clinical trial.4 The majority (54%) of
respondents expressed a belief in screening for lung cancer
for high-risk patients. This is a lower percentage than re-
ported on the previous survey (75%).2 Other studies have
reported a persistent belief in chest x-ray screening for lung
cancer, despite the lack of evidence of a mortality benefit.5–7
Nonrandomized CT screening studies have been performed,
and randomized trials are currently ongoing.8–10 It is intuitive
that the value of a screening test is related to how high the
risk of lung cancer is in an individual. Because no definition
of high risk was provided, a strict interpretation of the survey
results is not possible. It is interesting that the belief in
screening for high-risk individuals has decreased over time,
especially because the wording of this question is identical to
that in the 1999 survey. The detection of pulmonary nodules
on a CT scan of a patient with a high risk of lung cancer
frequently requires additional invasive procedures or fol-
low-up with additional noninvasive tests. The additional
testing can cause significant anxiety, inconvenience, and
morbidity to the patient. These factors may have tempered
enthusiasm for CT screening for lung cancer before definitive
evidence of a mortality benefit has been established. It should
be noted that this survey was performed before the publica-
tion of two recent articles on screening received significant
attention.11,12
The expected 5-year survival rate for patients with
resected stage I NSCLC in the literature is approximately
65%.13 Significant percentages of respondents in this survey
(26%) and in the previous survey (30%) have estimated the
5-year survival rate for stage I NSCLC at 85%. In the past, this
disease has been associated with a significant amount of pessi-
mism, particularly in fields outside of medical oncology.14 This
attitude may be changing among recent graduates; neverthe-
less, an overly optimistic impression of this disease also may
be detrimental to patient care.










All respondents 85 14 1
ACCP guidelines
Never read 85 14 1 0.89
Read 85 15 0
ACCP, American College of Chest Physicians.
TABLE 8. Chemotherapy Affects on Survival in Stage IV Disease
Survival Quality of Life
Improved (%) p Better (%) No Effect (%) Worse (%) p
All respondents 60 31 22 47
Pulmonary medicine 56 0.01 29 24 47 0.03
Thoracic surgery 74 42 11 46
Annual case load
2–10 50 0.01 18 26 55 0.26
11–25 50 30 25 45
25 65 35 19 46
ACCP guidelines
Never read 65 1.0 32 22 46 1.0
Read 59 31 22 47
ACCP, American College of Chest Physicians.
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In a medically fit patient with a lesion that is highly
suspicious for being a clinical stage I lung cancer, surgical
biopsy followed by lobectomy is recommended.15 Although
this answer was common among respondents, many (44%)
chose a PET scan. In fact, the guidelines are somewhat
confusing in this regard, because PET is given as an option in
the section on solitary pulmonary nodules (although it is
thought not to be sufficiently reliable for use in highly
suspicious lesions) and is recommended for most patients
with an operable lung cancer for staging purposes. Because of
the structure of the survey, it is unclear whether the PET scan
was the initial step before a biopsy or a staging test for
mediastinal or distant metastases.
The presence or absence of malignant involvement of
the mediastinal lymph nodes plays a critical role in determin-
ing whether a patient is potentially operable, and the proper
evaluation of the mediastinal lymph nodes can be challeng-
ing. The treatment beliefs for the majority of the respondents
on this and the previous survey were consistent with the
guidelines in electing to pursue a histological or cytological
evaluation of the mediastinal lymph nodes in a potentially
operable patient with enlarged lymph nodes on a CT scan.16
Some physicians elect to pursue PET scanning in this clinical
scenario. The previous survey did not include questions
related to the role of PET scans in mediastinal staging
because the survey was performed before the widespread
availability of PET scans. The utility of PET scans in patients
with enlarged lymph nodes is primarily for extrathoracic
staging; the PET scan does not avoid an invasive procedure,
because of the substantial false-negative and positive rate of
the PET scan in evaluating the mediastinal lymph nodes, and
because of the need to histologically or cytologically evaluate
for malignant involvement.17 The role of a preoperative PET
scan in a patient with normal-sized mediastinal lymph nodes
on CT scan (clinical stage I and II patients) is a controversial
subject. There is significant heterogeneity in this patient
population, and the probability of mediastinal lymph-node
involvement can vary depending on the anatomic location of
the primary, the tumor histology, and the presence or absence
of level 1 nodal enlargement.17 Data would suggest that a
positive PET scan should be confirmed with a biopsy; nev-
ertheless, it is controversial whether it is necessary to confirm
a negative PET scan with preoperative invasive staging. PET
scans also may have a role in extrathoracic staging in this
patient population. In a prospective study, PET scans detected
asymptomatic, extrathoracic metastases in 8% of clinical
stage I patients and in 18% of clinical stage II patients.18 The
variability in the responses also may reflect that a PET scan
may be used as part of a multistep process. A well-developed
set of treatment recommendations or evidence-based guide-
lines may be valuable for this clinical scenario.
Several questions investigated physicians’ beliefs re-
garding patients with locally advanced or resected NSCLC.
The guidelines recommend platinum-based chemotherapy in
combination with radiotherapy for patients with unresectable
stage III disease.19 There has been widespread support for this
recommendation among respondents in the survey (80%)
and in the previous survey (70%). Another survey of patterns
of care in locally advanced NSCLC has found that current
practice patterns in the United States generally match the
evidence-based literature in this clinical situation.20 The
guidelines state that there is no definitive improvement in
survival with PORT. According to the current survey, ap-
proximately 35% of physicians believe that PORT improves
survival; this response is similar to that in the previous survey
(40%). A separate survey has found that approximately 24%
of physicians would recommend PORT for a patient with
resected stage IIB disease.21 The PORT meta-analysis re-
vealed a potential detrimental effect on survival for patients
with early-stage disease—thus physicians’ belief, and the use
of PORT, may adversely impact survival in this patient
population.22 It should be noted that this survey was con-
ducted before the publication of a study that has revealed a
potential benefit of PORT in resected patients who were
found to have incidental lymph-node level 2 involvement.23
There was strong support for adjuvant chemotherapy
among respondents. Another survey has found a similarly
high acceptance of adjuvant chemotherapy.21 This is in con-
flict with the guidelines; nevertheless, the guidelines were
developed before the recent trials that have revealed improve-
ments in survival with adjuvant chemotherapy in resected
lung cancer. The fact that three recent randomized controlled
trials have revealed improvements in overall survival may
have contributed to the rapid acceptance of this therapy.24–26
The guidelines for stage IV disease state that in patients
with preserved functional status, chemotherapy improves
overall survival, has a palliative effect on disease-related
symptoms, and improves quality of life in comparison with
best supportive care.27 A surprisingly high percentage of
respondents do not believe that chemotherapy improves sur-
vival and believe that chemotherapy worsens quality of life.
In the previous survey, approximately a third of physicians
believed that chemotherapy provided a survival benefit. A
separate survey of physicians’ beliefs performed at approxi-
mately the same time as our original survey has found that
only 15% to 35% of physicians outside the field of medical
oncology would recommend chemotherapy for stage IV dis-
ease.2,28 The skepticism about the benefits of chemotherapy
in terms of survival and quality of life may decrease referrals
to medical oncology and reduce patient access to this therapy.
A review of the Surveillance, Epidemiology and End Re-
sults–Medicare database of patients with stage IIIB/IV has
revealed that only 31% of patients received chemotherapy.29
The fact that there were significant differences between
the treatment beliefs and the guidelines among physicians
may indicate that guidelines may not be completely accepted
even under favorable circumstances. Other surveys have
found significant differences between physician practices and
beliefs, and treatment guidelines and evidence-based medi-
cine.30 The reasons for this are probably multifactorial. By
definition, evidence-based guidelines cannot provide defini-
tive recommendations when there is limited or poor-quality
evidence, or when the evidence is ambiguous. The time it
takes to develop and publish guidelines makes it difficult to
incorporate new diagnostic tests and therapeutic advances,
such as PET scans and adjuvant therapy, into the guidelines.
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These factors can decrease the utility of guidelines in certain
clinical scenarios. Some physicians also may have an inher-
ent skepticism about the value of guidelines. Despite the
differences in treatment beliefs in select areas, the vast
majority of physicians have reported being familiar with the
guidelines and finding them valuable.
The optimal method of disseminating treatment guide-
lines has yet to be determined. Frequent methods of dissem-
ination include the publication of the guidelines in a peer-
reviewed journal or presentation at a national meeting. It is
possible that other educational methods, such as interactive
cases or lectures at local medical centers, may be more
effective at disseminating and encouraging the implementa-
tion of the guidelines. The availability of guidelines to the
general public on the Internet also could make the guidelines
more accessible and could increase the use of guidelines.
One weakness of this survey is the relatively small
sample size, which limits the sensitivity of the subset analy-
ses such as practice location, case load, and subspecialty.
Physicians generally have been a difficult group to survey
because of the time constraints of many physicians, the
frequent use of a multiple-choice format, and the need to
stereotype or generalize issues.31 Monetary incentives and
short questionnaires have been shown to increase the re-
sponse rates.31 The response rate with e-mail has not been
shown to be superior to that of postal mail.32 Many physicians
receive multiple survey requests, some of which are market-
ing surveys, and a significant amount of spam e-mail, which
may have contributed to the low response to this survey.
Another weakness of this survey is that the respon-
dents’ beliefs may not reflect the beliefs of the entire ACCP
membership. When the respondents’ characteristics are com-
pared with the demographics of the ACCP membership
within the United States, there are significant differences in
gender and the year that the training was completed (Table 9).
Because of differences in the terminology that the ACCP and
the survey used to record practice type, the only direct
comparison that could be performed was the percentage of
physicians reporting practicing in academic centers. A higher
percentage of survey respondents reported practicing at aca-
demic centers (Table 9). A direct evaluation for differences in
numbers of lung cancer cases seen by survey respondents and
the ACCP members was not feasible. The recipients of the
survey were randomly selected; nevertheless, physicians who
infrequently see lung cancer patients or who had not read the
guidelines may have elected not to answer the questionnaire.
These factors may have introduced biases into the survey
results.
CONCLUSIONS
The majority of physicians were familiar with the
guidelines and found them a valuable asset in the diagnostic
and therapeutic management of patients with NSCLC. Treat-
ment beliefs reflect the guidelines; nevertheless, in areas such
as the screening for lung cancer, use of PORT, and benefits of
chemotherapy for stage IV disease, treatment beliefs differ
significantly. These differences may adversely impact the
quality of patient care.
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